Amneal Pharmaceuticals, Inc. (AMRX) stock
AMRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 10/3062% above fair value
$21.23−0.15 (-0.70%)
Close on Nov 16, 2026Market cap $6.78BP/E 43.3Yield –
Amneal Pharmaceuticals cash
Cash and short-term investments held at the end of each period.
Amneal Pharmaceuticals's cash was $127.64M at Jun 30, 2026. For fiscal 2025 it was $282.03M, up 138.2% from the year before. Over ten years it grew 15.8% a year on average. The highest annual figure on record is $347.12M in fiscal 2020.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $282.03M | +138.2% |
| FY2024 | Dec 31, 2024 | $118.42M | +29.4% |
| FY2023 | Dec 31, 2023 | $91.54M | +159.9% |
| FY2022 | Dec 31, 2022 | $35.23M | -86.3% |
| FY2021 | Dec 31, 2021 | $256.74M | -26.0% |
| FY2020 | Dec 31, 2020 | $347.12M | +127.1% |
| FY2019 | Dec 31, 2019 | $152.82M | -30.1% |
| FY2018 | Dec 31, 2018 | $218.78M | +180.8% |
| FY2017 | Dec 31, 2017 | $77.92M | +107.5% |
| FY2016 | Dec 31, 2016 | $37.55M | -42.3% |
| FY2015 | Dec 31, 2015 | $65.11M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $127.64M | +78.4% |
| Q1 FY2026 | Mar 31, 2026 | $197.66M | +234.0% |
| Q4 FY2025 | Dec 31, 2025 | $282.03M | +138.2% |
| Q3 FY2025 | Sep 30, 2025 | $201.25M | +171.9% |
| Q2 FY2025 | Jun 30, 2025 | $71.54M | +63.5% |
| Q1 FY2025 | Mar 31, 2025 | $59.19M | +27.2% |
| Q4 FY2024 | Dec 31, 2024 | $118.42M | +29.4% |
| Q3 FY2024 | Sep 30, 2024 | $74.01M | -14.9% |
| Q2 FY2024 | Jun 30, 2024 | $43.77M | -59.9% |
| Q1 FY2024 | Mar 31, 2024 | $46.52M | -67.8% |
| Q4 FY2023 | Dec 31, 2023 | $91.54M | +159.9% |
| Q3 FY2023 | Sep 30, 2023 | $86.93M | -0.5% |
| Q2 FY2023 | Jun 30, 2023 | $109.28M | +18.8% |
| Q1 FY2023 | Mar 31, 2023 | $144.67M | -31.3% |
| Q4 FY2022 | Dec 31, 2022 | $35.23M | -86.3% |
| Q3 FY2022 | Sep 30, 2022 | $87.34M | -71.1% |
| Q2 FY2022 | Jun 30, 2022 | $91.98M | -67.0% |
| Q1 FY2022 | Mar 31, 2022 | $210.48M | -53.4% |
| Q4 FY2021 | Dec 31, 2021 | $256.74M | -26.0% |
| Q3 FY2021 | Sep 30, 2021 | $302.66M | +7.6% |
| Q2 FY2021 | Jun 30, 2021 | $278.31M | +4.6% |
| Q1 FY2021 | Mar 31, 2021 | $452.10M | +11.6% |
| Q4 FY2020 | Dec 31, 2020 | $347.12M | +127.1% |
| Q3 FY2020 | Sep 30, 2020 | $281.28M | +32.2% |
| Q2 FY2020 | Jun 30, 2020 | $266.14M | +384.8% |
| Q1 FY2020 | Mar 31, 2020 | $405.24M | +533.7% |
| Q4 FY2019 | Dec 31, 2019 | $152.82M | -30.1% |
| Q3 FY2019 | Sep 30, 2019 | $212.74M | +28.8% |
| Q2 FY2019 | Jun 30, 2019 | $54.89M | -10.8% |
| Q1 FY2019 | Mar 31, 2019 | $63.95M | +32.6% |
| Q4 FY2018 | Dec 31, 2018 | $218.78M | +180.8% |
| Q3 FY2018 | Sep 30, 2018 | $165.19M | +753.8% |
| Q2 FY2018 | Jun 30, 2018 | $61.52M | +27.6% |
| Q1 FY2018 | Mar 31, 2018 | $48.22M | +28.4% |
| Q4 FY2017 | Dec 31, 2017 | $77.92M | +19.7% |
| Q3 FY2017 | Sep 30, 2017 | $19.35M | – |
| Q2 FY2017 | Jun 30, 2017 | $48.22M | – |
| Q4 FY2016 | Dec 31, 2016 | $37.55M | – |
| Q4 FY2015 | Dec 31, 2015 | $65.11M | – |
See a number that looks wrong?